Exploring the active components and potential mechanisms of Rosa roxburghii Tratt in treating type 2 diabetes mellitus based on UPLC-Q-exactive Orbitrap/MS and network pharmacology

Table 1 Core targets of Rosa roxburghii Tratt fruit in the treatment of T2DM

Number	Core targets	Degree	Betweenness	Closeness
1	AKT1	128	4132.90	0.71
2	TNF	124	3789.15	0.69
3	SRC	108	1936.38	0.66
4	VEGFA	105	1366.52	0.65
5	EGFR	98	1590.71	0.64
6	CASP3	97	1146.73	0.64
7	MAPK3	96	1249.94	0.63
8	STAT3	94	1136.86	0.63
9	PPARG	85	2597.99	0.61
10	ESR1	83	1270.22	0.60
11	mTOR	81	980.66	0.61
12	PTGS2	79	1135.57	0.60
13	MAPK1	78	1111.02	0.60

AKT1 serine/threonine kinase 1, TNF tumor necrosis factor, SRC steroid receptor coactivator, VEGFA vascular endothelial growth factor A, EGFR epidermal growth factor receptor, CASP3 caspase-3, MAPK3 mitogen-activated protein 3, STAT3 signal transducer and activator of transcription 3, PPARG peroxisome proliferator-activated receptor gamma, ESR1 estrogen receptor 1, mTOR mammalian target of rapamycin, PTGS2 prostaglandin-endoperoxide synthase 2, MAPK1 mitogen-activated protein kinase 1

ISSN: 1749-8546